Idera Pharmaceuticals, Inc.

Hybridon, Inc.

Worcester Foundation for Experimental Biology

University of Massachusetts

Worcester Foundation for Biomedical Research

Other

The Norwegian Radium Hospital Research Foundation

The General Hospital Corporation

Mount Sinai School of Medicine

Sudhir Agrawal

Ekambar R Kandimalla

Dong Yu

Daqing Wang

Lakshmi Bhagat

Qiuyan Zhao

Radhakrishnan P Iyer

Mallikarjuna Putta

Ivan Habus

Yukui Li

Paul C Zamecnik

Tao Lan

FuGang Zhu

Ireneusz Nowak

Jin-Yan Tang

Ruiwen Zhang

Valeri Metelev

Wayne Jiang

Weitian Tan

Theresa Devlin

Fu-Gang Zhu

Thoru Pederson

Zhiwei Jiang

Robert B Diasio

Jamal Temsamani

Sandra Mayrand

Oystein Fodstad

Olav Engebraaten

Gunhild Maelandsmo

Eivind Hovig

Peter M Palese

Rajendra K Pandey

Josef M Leiter

Jiandong Chen

Eric Von Hofe

David E Wolf

Charles A Marotta

Richard A Cardullo

Mao-Jun Guo

A Padmapriya

Jessica Seitzer

Nicola LaMonica

Weiwen Jiang

Michael Reardon

Weitan Tan

Victoria Jane Philbin

Ronald E Majocha

Jin-Yang Tang

Jinyan Tang

Nan-Hui Ho

Susan Meschwitz

Xianzhi Mao

Bhagat Lakshmi

Ekambar M Kandimalla

Quiyan Zhao

Wang Daqing

Zhu Fugang

Millikarjuna Putta

The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.

Immune modulation with TLR9 agonists for cancer treatment

The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5'-ends to allow the presence of two or more accessible 3&#x2032;-ends.

Compositions for inhibiting checkpoint gene expression and uses thereof

The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.

Toll-like receptor 9 antagonist and methods of use thereof

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8

The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.

Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9

Growing community of inventors

Shrewsbury, MA, United States of America

Sudhir Agrawal